NET ZERO INFRASTRUCTURE PLC

Regulatory Filings • Jun 19, 2024

National Storage Mechanism | Additional information

RNS Number : 8928S

Net Zero Infrastructure PLC

19 June 2024

19 June 2024

NET ZERO INFRASTRUCTURE PLC

("NZI" or the "Company")

Update on QuiaPEG Transaction

Net Zero Infrastructure Plc, a special purpose acquisition company formed with the intention to acquire renewable or clean energy technology companies and to finance, develop and promote those environmentally sound projects internationally, is pleased to announce it has now completed its third-party independent valuation of the intellectual property assets of QuiaPEG Pharmaceuticals AB and the assets are estimated to be worth around £30m, following the announcement made on 16 February 2024.

QuiaPeg is a drug development company based on a patented drug delivery platform, Uni-Qleaver®, and the company develops improved and patentable forms of drugs under development or already approved by regulatory authorities. QuiaPEG's shares are admitted on trading on Nasdaq First North Growth Market.

Work will continue on the prospectus and finalising the license agreement so the transaction can be completed in the coming months. 

Enquiries:

For further information, please visit - www.nziplc.com

Contact Details

Net Zero Infrastructure plc Mike Ellwood - Non-Executive Chairman	+44 (0) 799 932 9382
Axis Capital Markets Limited (Company Broker) Richard Hutchison	+44 (0) 203 026 0320
IFC Advisory (Financial PR) Graham Herring Tim Metcalfe	+44 (0) 203 934 6630

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDEAEKPFFFLEFA